AIM ImmunoTech
AIM
AMEX: AIM
IndustryBiopharmaceutical
Headquarters
Ocala, Florida
,
USA
Key people
CEO Thomas K. Equels, J.D.
COO Peter W. Rodino III, J.D.
CFO Ellen Lintal
ProductsAmpligen
Alferon
ServicesCancer and immunotherapy research
Total assets$ 64.584 million Increase (2020[1])

AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders.[2] Founded in 1990, the company has twenty-three employees.[3]

The company has created an immunomodulatory double stranded RNA drug called Ampligen.[4]

It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome.[5]

History

The company's logo when it was named Hemispherx Biopharma, Inc.

On April 3, 2001, Hemispherx Biopharma, Inc. adjusted and restated its 1999 financial statements to reflect charges relating to an extension of the exercise period to certain warrants as of February 1999.[6]

On April 3, 2006, Hemispherx Biopharma, Inc. restated financial results for 2003 and 2004 due to accounting mistakes related to debentures and warrants issued between March 2003 and August 2005.[7]

In June, 2018, Hemispherx announced that Ampligen had shown effectiveness in activating the TLR3 without triggering T-cell regulatory activities, offering a potentially effective way to treat tumors.[8]

As of June 2019, Hemispherx is operating five studies examining the viability of Ampligen for combating Ovarian cancer, to which end it has also raised tens of millions of dollars in shareholder capital.[9]

On September 3, 2019, Hemispherx Biopharma was renamed to AIM Immunotech.[10]

On March 12, 2020, Hemispherx Biopharma announced that they were testing a possible treatment for the novel coronavirus, the virus believed to cause the symptoms of COVID-19.[11]

References

  1. ↑ "Date: 3/31/2021 Form: 10-K - Annual Report, for AIM IMMUNOTECH INC".
  2. ↑ Greenberg, Herb (1998-09-18). "Battle Royale Brewing: Hemispherx Biopharma and Asensio Tangle". TheStreet.com. Archived from the original on 6 June 2011. Retrieved 24 August 2009.
  3. ↑ "Hemispherx Biopharma, Inc". BusinessWeek. Archived from the original on 22 September 2012. Retrieved 24 August 2009.
  4. ↑ "Hemispherx licensed for chemical compound". Philadelphia Business Journal. 2006-08-29. Archived from the original on 25 October 2012. Retrieved 24 August 2009.
  5. ↑ "Hemispherx Biopharma Inc. (use of Ampligen for chronic fatigue syndrome)". Philadelphia Business Journal. 2000-10-06. Retrieved 24 August 2009.
  6. ↑ "FORM 10-K/A AMENDMENT NO. 2 SECURITIES AND EXCHANGE COMMISSION".
  7. ↑ "Hemispherx delays 2005 statement".
  8. ↑ "Hemispherx Biopharma (HEB) Highlights New Data Showing Ampligen's Positive Role in Reprograming Tumor Microenvironment". Street Insider. 5 June 2018.
  9. ↑ Hemispherx Reports 2019 First Quarter Financial Results
  10. ↑ "Brief-Hemispherx Biopharma Inc Changes Name To Aim Immunotech Inc". Reuters. 2019-08-23. Archived from the original on 2020-01-23. Retrieved 2020-01-23 – via MSN.
  11. ↑ "Increasing number of biopharma drugs target COVID-19 as virus spreads". www.bioworld.com. Retrieved 2020-09-13.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.